Patents Assigned to Hadasit
  • HIGH THROUGHPUT SCREENING OF AGENTS ON DOPAMINERGIC NEURONS
    Publication number: 20190137482
    Abstract: A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Talya MORDECHAI DANIEL, Ofer WISER, Benjamin Eithan REUBINOFF
  • HYPERIMMUNE COLOSTRUM IN THE MODULATION AND TREATMENT OF CONDITIONS ASSOCIATED WITH THE MAMMALIAN MICROBIOME
    Publication number: 20190134096
    Abstract: Provided are methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. The methods and compositions are based on preparations of hyperimmune colostrum enriched with antibodies for lipopolysaccharides (anti-LPS), which directly or indirectly impact on the composition of mammalian microbiome and are applicable to alleviation and treatment of various forms of renal failure, hypertension, heart disease, atherosclerosis and sepsis, and various psychiatric and neurobehavioral conditions.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventor: Yaron ILAN
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 10266897
    Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: April 23, 2019
    Assignee: Hadasit Medical Research and Development Ltd.
    Inventor: Rifaat Safadi
  • POMEGRANATE OIL FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20190070111
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Application
    Filed: November 8, 2018
    Publication date: March 7, 2019
    Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth GABIZON, Haim OVADIA, Oded ABRAMSKY, Shlomo MAGDASSI, Liraz LARUSH
  • MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPS
    Publication number: 20190053487
    Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
    Type: Application
    Filed: February 26, 2017
    Publication date: February 21, 2019
    Applicants: NOBIO LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Nathan ZALTSMAN, Ervin I. WEISS
  • Targeting of innate immune response to tumor site
    Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Plasminogen activator mutants as anti-fibrinolytic agents
    Patent number: 10188706
    Abstract: The invention relates to an anti fibrinolytic composition comprising at least one tPA mutant that carries at least one point mutation substituting Ser481 to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 29, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Abd Higazi, Nuha Hijazi
  • USE OF GUAIACOL FOR THE PREVENTION AND TREATMENT OF GLYCOGEN STORAGE DISEASE
    Publication number: 20190015355
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicants: The Trustees of Couumbia University in the City of New York, Hadasit Medical Research Services and Development Ltd.
    Inventors: Hasan Orhan AKMAN, Salvatore DIMAURO, Or KAKHLON
  • Methods of obtaining cell populations enriched with desired cells
    Patent number: 10174285
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 8, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff
  • TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20190000854
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: January 3, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • Treatment of hepatic encephalopathy and liver cirrhosis
    Patent number: 10166202
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 1, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot Berry, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • Pomegranate oil for preventing and treating neurodegenerative diseases
    Patent number: 10154961
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: December 18, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • SUPPLEMENTATION OF MILK FORMULAS WITH MICROVESICLES ISOLATED FROM MILK
    Publication number: 20180343882
    Abstract: Provided are microvesicles isolated from milk, compositions thereof and uses for the preparation of milk formulas. Further provided are microvesicles, including exosomes and/or fat globules which encapsulate various miRNA molecules and uses thereof, as exemplified by supplementing milk formulas.
    Type: Application
    Filed: November 29, 2016
    Publication date: December 6, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Shimon REIF, Regina GOLAN
  • ATTENUATED OR INACTIVATED PATHOGENIC ESCHERICHIA COLI FOR TREATING UROGENITAL CANCER
    Publication number: 20180333439
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 22, 2018
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer MANDELBOIM, Gilad Benjamin BACHRACH, Chamutal GUR, Vladimir YUTKIN
  • Preparation of Retinal Pigment Epithelium Cells
    Publication number: 20180312805
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 1, 2018
    Applicants: CELL CURE NEUROSCIENCES LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER, Osnat BOHANA-KASHTAN, Ofer WISER
  • Methods and compositions for treating viral infections
    Patent number: 10111884
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: October 30, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., The Hong Kong University of Science and Technology
    Inventors: Richard K. Haynes, Dana G. Wolf
  • Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
    Patent number: 10087232
    Abstract: A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: October 2, 2018
    Assignees: Protalix Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron Ilan, Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski
  • Allogeneic tumor cell vaccination
    Patent number: 10064927
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • LARGE SCALE PRODUCTION OF RETINAL PIGMENT EPITHELIAL CELLS
    Publication number: 20180216064
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER
  • TYPE III DEIODINASE INHIBITORS AND USES THEREOF
    Publication number: 20180215709
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Application
    Filed: March 16, 2015
    Publication date: August 2, 2018
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard LERER, Mugesh GOVINDASAMY, Tzuri LIFSCHYTZ